Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
- Authors
- Hong, Jihyung; Novick, Diego; Montgomery, William; Victoria Moneta, Maria; Duenas, Hector; Peng, Xiaomei; Maria Haro, Josep
- Issue Date
- Oct-2015
- Publisher
- DOVE MEDICAL PRESS LTD
- Keywords
- depression; antidepressant; duloxetine; SSRI; quality of life
- Citation
- PATIENT PREFERENCE AND ADHERENCE, v.9, pp.1481 - 1490
- Journal Title
- PATIENT PREFERENCE AND ADHERENCE
- Volume
- 9
- Start Page
- 1481
- End Page
- 1490
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/11951
- DOI
- 10.2147/PPA.S89870
- ISSN
- 1177-889X
- Abstract
- Purpose: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico. Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 MDD patients without sexual dysfunction. QoL was measured using the EQ-5D instrument. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16), while pain severity was measured using the pain items of the Somatic Symptom Inventory. Regression analyses were performed to compare the levels of QoL between duloxetine-treated (n=556) and SSRI-treated (n=776) patients, adjusting for baseline patient characteristics. Results: These MDD patients, on average, had moderately impaired QoL at baseline, and the level of QoL impairment was similar between the duloxetine and SSRI groups (EQ-5D score of 0.46 [SD=0.32] in the former and 0.47 [SD=0.33] in the latter, P=0.066). Both descriptive and regression analyses confirmed QoL improvements in both groups during follow-up, but duloxetine-treated patients achieved higher QoL. At 24 weeks, the estimated mean EQ-5D score was 0.90 in the duloxetine cohort, which was statistically significantly higher than that of 0.83 in the SSRI cohort (P<0.001). Notably, pain severity at baseline was also statistically significantly associated with poorer QoL during follow-up (P<0.001). In addition, this association was observed in the subgroup of SSRI-treated patients (P<0.001), but not in that of duloxetine-treated patients (P=0.479). Conclusion: Depressed patients treated with duloxetine achieved higher QoL, compared to those treated with SSRIs, possibly in part due to its moderating effect on the link between pain and poorer QoL.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 사회과학대학 > 의료경영학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/11951)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.